REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

19/02/2020 07:00

RNS Number : 3828D
AstraZeneca PLC
19 February 2020
 


19 February 2020 07:00 GMT
 
 
TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
 
AstraZeneca PLC (the Company) announces that, on 17 February 2020, it was notified by Michel Demaré, a Non-Executive Director of the Company, that, on 17 February 2020, Mr Demaré purchased 700 Ordinary Shares of $0.25 each in the Company (Shares) at a price of £73.13 per Share.
 
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
 




1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)
 


Name
 
 


Michel Demaré




2
 


Reason for the notification
 




a)
 


Position/status
 
 


Non-Executive Director




b)
 


Initial notification /Amendment
 
 


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 




a)
 


Name
 
 


AstraZeneca PLC




b)
 


LEI
 
 


PY6ZZQWO2IZFZC3IOL08




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 
 




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 
 


Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 




b)
 


Nature of the transaction
 
 


Share purchase




c)
 


Price(s) and volume(s)
 
 


 




Price(s)
 


Volume(s)




GB£73.13


700




 
 




d)
 


Aggregated information
 
 
- Aggregated volume
 
 
- Price
 
 


Not applicable - single transaction
 




e)
 


Date of the transaction
 
 


17 February 2020




f)
 


Place of the transaction
 
 


XLON




 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
 




 
Media Relations


 


 




Gonzalo Viña


 


+44 203 749 5916




Rob Skelding


Oncology


+44 203 749 5821




Rebecca Einhorn


Oncology


+1 301 518 4122




Matt Kent


BioPharmaceuticals


+44 203 749 5906




Jennifer Hursit


Other


+44 203 749 5762




Christina Malmberg Hägerstrand


Sweden


+46 8 552 53 106




Michele Meixell


US


+1 302 885 2677




 


 


 




Investor Relations


 


 




Thomas Kudsk Larsen


 


+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


BioPharmaceuticals (cardiovascular; metabolism)


+44 203 749 5711




Nick Stone


BioPharmaceuticals (respiratory; renal)


+44 203 749 5716




Josie Afolabi


Other medicines


+44 203 749 5631




Craig Marks


Finance, fixed income


+44 7881 615 764




Jennifer Kretzmann


Corporate access, retail investors


+44 203 749 5824




US toll-free


 


+1 866 381 72 77






Adrian Kemp

Company Secretary

AstraZeneca PLC




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHUWSVRRAUUAAR